Osteoarthritis Drugs Market Report | the Demand for the Market Will Drastically Increase in the Future

The most prevalent type of arthritis is osteoarthritis, often known as degenerative joint disease. It can affect a variety of joints throughout the body. The condition, on the other hand, has a significant impact on the knees, neck, lower back, hips, and tiny finger joints.


Injury, obesity, and a variety of other variables all contribute to osteoarthritis. The affected body portion has severe joint pain and stiffness as a result of this condition. Swelling in joints, tingling in the legs and arms, and a reduced range of motion are all indications of osteoarthritis. The Osteoarthritis Drugs Market is predicted to rise because of the high prevalence of rheumatoid arthritis. Furthermore, the Osteoarthritis Drugs Market is predicted to rise due to rising obesity rates linked to a deskbound lifestyle over the forecast period. Obesity puts additional pressure on the knees and hips, causing the cushion joints to wear down more quickly.


However, the provision of just symptomatic treatment rather than a permanent cure for osteoarthritis is projected to be a key stumbling block to the Osteoarthritis Drugs Market expansion. Regular use of nonsteroidal anti-inflammatory medicines (NSAIDs) in the treatment of osteoarthritis might result in cardiovascular events such as heart attack and stroke, which is predicted to limit market expansion.


Because of the growing senior population, which is at high risk of osteoarthritis, North America dominates the worldwide Osteoarthritis Drugs Market. According to a factsheet published by the Centers for Disease Control and Prevention (CDC), between 2013 and 2015, 29.3 percent of people aged 45 to 64 and 49.6 percent of people aged 65 and up were diagnosed with arthritis in the United States. Similarly, according to the National Center for Biotechnology Information (NCBI), approximately 14 million people were diagnosed with symptomatic knee osteoarthritis in December 2016, with around 2 million people under 45 years of age being diagnosed, and 6 million cases being diagnosed in people aged 45 to 64 years and above 65 years in the United States.


Pfizer Inc., Abbott, Eli Lilly and Company, ABIOGEN PHARMA S.p.A, Horizon Pharma plc., Ferring B.V., Merck Sharp & Dohme Corp., Medivir, Bioventus, Inc., Sanofi, Flexion Therapeutics, Inc., Regeneron, and GlaxoSmithKline Plc are some of the major key players in the Osteoarthritis Drugs Market


Comments

Popular posts from this blog

Significance of EHealth Software And Services

The OKR Software Market Is Estimated To Increase At A CAGR Of 12.60 Percent During The Forecast Period

Broadcast Switchers Market Report | the Demand for the Market Will Drastically Increase in the Future